This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Shiga University of Medical Science. Active years: 2015.
Company Filing History:
Years Active: 2015
Title: Hirohito Ishigaki: Innovator in Immunosuppressive Technologies
Introduction
Hirohito Ishigaki is a notable inventor based in Otsu, Japan. He has made significant contributions to the field of immunosuppressive materials, showcasing his expertise through innovative patents. His work is particularly relevant in medical science, where advancements in immunosuppressive technologies can have profound impacts on patient care.
Latest Patents
Ishigaki holds a patent for an "Immunosuppressive cell-capturing material and immunosuppressive cell-capturing column." This invention discloses a unique immunosuppressive cell-capturing material that comprises a molded body. The material includes a readily hydrolyzable condensation polymer with an amino group, a poorly hydrolyzable polymer coating, and a ligand-conjugated poorly hydrolyzable polymer. The ligands are selected from a diverse group, including various amino groups and aminoglycosidic compounds. The content of the amino group in the molded body is specified to be 150 μmol/g or less. Additionally, the invention includes an immunosuppressive cell-capturing column filled with this capturing material.
Career Highlights
Hirohito Ishigaki is affiliated with Shiga University of Medical Science, where he continues to advance his research and development in immunosuppressive technologies. His work is characterized by a commitment to improving medical treatments and patient outcomes through innovative solutions.
Collaborations
Ishigaki collaborates with esteemed colleagues, including Yuji Ueda and Yasushi Itoh. Their combined expertise enhances the research and development efforts in their field, fostering a collaborative environment that promotes innovation.
Conclusion
Hirohito Ishigaki's contributions to immunosuppressive technologies exemplify the impact of innovative thinking in medical science. His patent reflects a significant advancement that could benefit many patients in need of effective immunosuppressive treatments.